EMS-Chemie Q1 sales fall on strong franc despite higher volumes, EBIT

EMS-Chemie reported Q1 2026 net sales of CHF 487 million, down 6.6% y/y; a stronger Swiss franc accounted for a 7.3 percentage-point drag, implying underlying volumes rose across both segments. EBIT improved versus the prior year; High Performance Polymers sales were CHF 439m (-6.4%) and Specialty Chemicals CHF 48m (-8.1%), each carrying the same 7.3pp currency headwind. For full-year 2026 the firm expects net sales below prior year due to FX but forecasts net operating income (EBIT) slightly above the prior-year level, and highlighted strong demand in energy-saving systems, EV, healthcare and robotics while flagging higher energy, freight and raw material costs.

Analysis

A strong CHF, not underlying demand weakness, is the dominant near-term headline for EMS; the company’s underlying volumes and operating leverage are intact, so market reaction should be judged through an FX lens rather than pure revenue growth. That creates a deterministic two-variable valuation: operational momentum (volumes/EBIT) vs reported CHF translation — if CHF stabilizes or is hedged, multiple expansion is likely within 6–12 months as investors re-rate recurring margin improvement.

The firm’s early US-localization of production is a structural competitive hedge against further tariff escalation, creating a second-order advantage versus European competitors that must either absorb duties or rework supply chains at higher capex and lead times. Expect market-share shifts to occur on a 3–12 month cadence as OEMs (EV and medical device makers) prioritize suppliers with local content to avoid customs friction and freight volatility.

Input-cost inflation remains the binding short-term risk: higher energy, freight and raw-materials will press margins until explicit pass-through contracts are implemented, typically a 1–3 quarter lag. Key catalysts to watch are SNB guidance and CHF moves (days–weeks tied to geopolitical shocks), quarterly EBIT revisions (next 1–2 reports) and freight/energy price trajectories — any persistent CHF re-appreciation or slower-than-expected pricing pass-through would compress realized margins and re-price the stock downward.

Key Decisions for Investors

• Long EMSN equity (6–12 month horizon) size 3–5% NAV. Hedge FX exposure by selling CHF forward for the same tenor or buying EUR/CHF calls to neutralize translation risk. R/R: if CHF stabilizes and market recognizes EBIT resilience, target 20–35% upside; downside if CHF strengthens further or pass-through lags ~10–20% loss.
• Pair trade: Long EMSN / Short Arkema (AKE, 6–12 months) to express premium for US-localized polymers. Position aims to capture 10–15% relative outperformance as customers favor localized supply; risk is symmetric raw-material inflation hitting both names — stop if spread reverses >15%.
• Options sleeve to express convexity with limited capital: buy 9–12 month EMSN call spread (bull call spread) sized to 1–2% NAV to cap premium cost. R/R: asymmetry ~3:1 if operational momentum and FX backdrop improve; max loss limited to paid premium if story disappoints.
• Macro hedge / tactical FX: if geopolitical risk spikes (Iran tensions), expect CHF safe-haven flows — run a tactical CHF sell via EUR/CHF put spread (3–6 months) only after signs of SNB verbal intervention or CHF breaking multi-week highs. Use as protection against headline-driven CHF re-strengthening; carry cost is the primary risk if CHF weakens.